FLOW MANAGEMENT DEVICES acquired by IDEX CORPORATION

The global safety technology leader has successfully finalized the acquisition of the total share capital of the target, marking a significant reinforcement of its gas detection capabilities within the Process Safety division. This strategic transaction represents a definitive move to incorporate specialized methane detection technology into the group's broader environmental monitoring portfolio. The strategic rationale for the move centers on the acquirer’s objective to broaden its technical operational depth in the natural gas utility market, where tightening regulatory standards regarding methane emissions and worker protection are driving structural growth

In one of the largest European LBOs in history, Thyssenkrupp AG agreed to sell its Elevator division to a consortium led by Advent and Cinven for an Enterprise Value of €17.2 billion. The transaction followed a highly competitive auction process where strategic bidders, such as Kone, were sidelined due to significant antitrust risks. To facilitate the deal and maintain a strategic link, Thyssenkrupp reinvested €1.25 billion to retain a minority stake. The sale was a critical move for the German conglomerate to address its high debt levels and offset massive losses in its steel and automotive sectors

Nordic Capital signed an agreement to acquire Consilium Marine & Safety from its parent company, Consilium AB, in a complex carve-out transaction. The deal includes the transfer of the "Consilium" brand rights to the new standalone entity. The strategic rationale is to liberate the division from the conglomerate structure of the listed parent, allowing it to operate as an independent, focused safety champion. Nordic Capital plans to deploy its operational resources to accelerate growth through R&D investment, commercial excellence initiatives, and a targeted M&A strategy to consolidate the fragmented safety market

The transaction establishes a phased corporate acquisition framework enabling Marel to secure an initial minority stake in Curio before graduating to majority consolidation, with a final call option structured to absorb the remaining equity within a four-year horizon. This staggered ownership transition effectively de-risks the integration process by preserving management continuity under the target's founding chief executive, thereby maintaining critical technical oversight and stabilizing long-term client relationships in the core Nordic and British markets

The acquisition of Gatan marks a definitive technical reinforcement of the group’s presence in the global analytical instrumentation market. The strategic rationale for this transaction centers on a "portfolio-integration" play, merging the target's industry-leading electron microscopy technologies with the group’s extensive Electronic Instruments Group (EIG) infrastructure. This fusion effectively creates a specialized powerhouse in the high-end research sector, providing the organization with the proprietary cameras, energy filters, and software required to support the world’s most sophisticated laboratory workflows

This management buy-out transaction represents a significant milestone in the evolution of the company's shareholder structure, with the exit of Targa Capital's family office and a group of private investors who had supported the company since its initial management buy-in in 2011 and subsequent restructuring in 2016. Under the president's leadership, the company has achieved an adjusted ebitda margin above 25%, while exports now account for nearly 30% of sales, following an international expansion strategy

The acquisition of BTG marks a significant expansion of technical capabilities within the specialized pulp and paper industry, creating a more comprehensive portfolio for global customers. This strategic operation follows a definitive agreement to integrate specialized sensor and automation technologies into a larger industrial technology group. The merger aims to enhance the delivery of high-value solutions that optimize production efficiency and paper quality on a global scale. By combining deep research and development expertise with extensive full-line industrial manufacturing capabilities, the new partnership is well-positioned to drive innovation in process automation

Agilent has finalized the acquisition of BioTek Instruments in an all-cash transaction, a maneuver designed to fundamentally expand its capabilities in the critical cell analysis technology sector. The strategic rationale for this transaction centers on a "workflow-simplification" play, merging the target's industry-leading expertise in microplate detection and imaging with the group’s established presence in live-cell, real-time analysis. This structural alignment provides the organization with the scientific talent and technological hardware required to address the increasing complexity of immunotherapy and biologics research

Teledyne Technologies Incorporated has successfully completed the acquisition of the gas and flame detection business of 3M. The transaction represents a significant corporate carve,out from 3M’s Safety and Industrial Division. The acquisition includes several global brands such as Oldham, Simtronics, GMI, and Detcon, as well as select products from the Scott Safety line (though 3M retains the Scott Safety brand name itself). Approximately 500 employees joined Teledyne as part of the transition. The strategic rationale for the deal is the high degree of technological and market overlap with Teledyne’s existing environmental instrumentation businesses

Danaher has finalized an agreement to acquire GE Biopharma in a transformational all-cash transaction, an operation designed to fundamentally redefine the landscape of the global bioprocessing market. The strategic rationale for this transaction centers on a "Bioprocessing-Powerhouse" play, merging the target's industry-leading technical operational depth in chromatography and cell culture with the group’s established life sciences platform and the power of the Danaher Business System. This structural alignment provides the organization with the scientific talent and technological hardware—specifically across upstream and downstream workflows—required to address the surging global demand for biologic drug development